SCHEMBL25201547

SCHEMBL25201547

c1ncc2c(-c3ccc4nccn4n3)c[nH]c2n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 1/20 0.56
DYRK1A Q13627 4/20 0.47
CLK4 Q9HAZ1 5/20 0.42
GSK3A P49840 3/20 0.42
RPS6KA3 P51812 3/20 0.42
MAP2K1 Q02750 3/20 0.42
ALK Q9UM73 3/20 0.42
DYRK1B Q9Y463 3/20 0.42
JAK2 O60674 2/20 0.42
RET P07949 2/20 0.42
KDR P35968 2/20 0.42
LIMK1 P53667 2/20 0.42
MAPK14 Q16539 2/20 0.42
RPS6KA5 O75582 1/20 0.40
LATS1 O95835 1/20 0.39
MAP4K4 O95819 4/20 0.38
PRKACA P17612 4/20 0.38
CDK8 P49336 4/20 0.38
LRRK2 Q5S007 3/20 0.38
DAPK3 O43293 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30349241 1.00 PRKCI (0.56) PRKCIDYRK1ACLK4GSK3ARPS6KA3
SCHEMBL30347070 0.82 PRKCI (0.51) PRKCIDYRK1ACLK4GSK3ARPS6KA3
SCHEMBL25157602 0.82 PRKCI (0.51) PRKCIDYRK1ACLK4GSK3ARPS6KA3
SCHEMBL26174511 0.82 PRKCI (0.66) PRKCIDYRK1ACLK4GSK3ARPS6KA3
SCHEMBL30406657 0.80 DYRK1A (0.48) PRKCIDYRK1ARPS6KA5LATS1TBK1
SCHEMBL25158040 0.80 PRKCI (0.51) PRKCIDYRK1ACLK4GSK3ARPS6KA3
SCHEMBL25201242 0.80 DYRK1A (0.48) PRKCIDYRK1ARPS6KA5LATS1TBK1
SCHEMBL26174746 0.80 PRKCI (0.54) PRKCIDYRK1ACLK4GSK3ARPS6KA3
SCHEMBL26174664 0.80 PRKCI (0.54) PRKCIDYRK1ACLK4GSK3ARPS6KA3
SCHEMBL26174709 0.80 PRKCI (0.54) PRKCIDYRK1ACLK4GSK3ARPS6KA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 US claimed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 US disclosed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 PRKCI 1043/4885DYRK1A 1/4885CLK4 1142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.